Treating cardiomyopathy depends on which type you have, how severe your symptoms are, and how well your heart is pumping. There is no single cure for most forms of cardiomyopathy, but a combination of medications, lifestyle changes, implantable devices, and in some cases surgery can slow the disease, relieve symptoms, and significantly extend life. The goals are consistent across types: reduce the workload on your heart, prevent dangerous heart rhythms, and manage fluid buildup.
Medications for Heart Failure Symptoms
When cardiomyopathy weakens the heart’s pumping ability (a condition called reduced ejection fraction), the current standard of care calls for four categories of medication used together. These include drugs that block the hormonal stress response on your heart (beta-blockers and a class that relaxes blood vessels while protecting heart muscle), a newer drug class originally developed for diabetes that helps the kidneys remove excess sodium and fluid, and a traditional diuretic to reduce fluid retention. The 2024 expert consensus from the American College of Cardiology emphasizes starting these medications early rather than waiting for symptoms to worsen.
Each drug works on a different part of the cycle that makes heart failure worse. Beta-blockers slow the heart rate and lower blood pressure, giving the heart more time to fill and less resistance to pump against. The kidney-protective drugs reduce hospitalizations and improve survival even in people without diabetes. Diuretics provide the most noticeable day-to-day relief by pulling excess fluid out of your lungs and legs.
Treating Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy (HCM) is different from the dilated type because the heart muscle is too thick rather than too weak. When the thickened muscle blocks blood flow out of the heart, it’s called obstructive HCM, and it has its own targeted treatment.
A newer class of medication called cardiac myosin inhibitors works by reducing the excessive contraction force in the thickened muscle. In the landmark EXPLORER-HCM trial published in The Lancet, 37% of patients taking the drug met the primary endpoint of improved exercise capacity and symptom relief, compared with 17% on placebo. Patients experienced a meaningful drop in the pressure gradient blocking blood flow and gained about 1.4 mL/kg per minute of peak oxygen consumption, which translates to noticeably better stamina during daily activities. Roughly 65% of treated patients improved by at least one functional class, meaning activities that previously caused breathlessness became manageable.
When medications alone aren’t enough, two procedures can physically reduce the obstruction. Surgical myectomy removes a strip of the thickened muscle, while alcohol septal ablation uses a targeted injection to shrink the overgrown tissue. A propensity-matched study comparing the two found no difference in long-term survival, but myectomy delivered better immediate results: the resting pressure gradient dropped to essentially zero after surgery, compared to a residual gradient of 21 mm Hg after ablation. More importantly, patients who had ablation were far more likely to need a repeat procedure (about 33 times more likely in the study). Myectomy at an experienced center is generally preferred for younger patients and those with very thick muscle walls, while ablation may suit older patients or those with higher surgical risk.
Implantable Devices
Two types of implanted devices play a major role in cardiomyopathy treatment. An implantable cardioverter-defibrillator (ICD) monitors your heart rhythm around the clock and delivers a shock if it detects a life-threatening arrhythmia. A cardiac resynchronization therapy device (CRT) coordinates the timing of your heart’s contractions when the electrical signals have become disorganized, which is common as cardiomyopathy progresses.
The decision to place an ICD depends on your ejection fraction and whether you’ve already had a dangerous arrhythmia. Patients with an ejection fraction at or below 35% who have experienced sustained abnormal rhythms receive the strongest recommendation for an ICD. But even patients with higher ejection fractions may qualify if they’ve survived a cardiac arrest with no reversible cause found. The 2025 appropriate use criteria from the ACC, AHA, and partnering societies assign the highest scores (8 or 9 out of 9) to these scenarios.
CRT devices are typically considered when your ejection fraction is 35% or below and the electrical signal traveling through your heart is significantly delayed (visible as a wide pattern on an EKG). The device uses leads placed in both lower chambers to restore coordinated pumping, which can sometimes improve ejection fraction by 5 to 15 percentage points over several months.
Managing Arrhythmogenic Cardiomyopathy
Arrhythmogenic cardiomyopathy (sometimes called ARVC) replaces heart muscle with fatty or scar tissue, primarily in the right ventricle. This creates electrical instability that makes dangerous heart rhythms the central threat rather than pump failure. Treatment focuses on three pillars: exercise restriction, rhythm-controlling medications, and ICD placement for those at high risk of sudden cardiac arrest.
Exercise restriction applies to everyone with a definite or even borderline diagnosis. Intense physical activity increases the mechanical stress on the weakened wall and can trigger fatal arrhythmias. Beta-blockers are first-line therapy to blunt the adrenaline surges that provoke abnormal rhythms. For patients with breakthrough arrhythmias despite beta-blockers, additional anti-arrhythmic medications or catheter ablation (a procedure that targets and destroys the tissue generating rogue electrical signals) are options.
Diet, Fluid, and Exercise Guidelines
Sodium and fluid management has a direct, measurable effect on how you feel day to day. When your heart can’t pump efficiently, excess salt causes your body to retain fluid, which pools in your lungs and extremities. Mayo Clinic guidelines suggest limiting sodium to 2,000 mg per day and total fluid intake to about 50 ounces (roughly 1.5 liters), including water-rich foods like fruit. The Heart Failure Society of America allows up to 3,000 mg of sodium for milder cases but recommends staying under 2,000 mg for moderate to severe heart failure.
Practical strategies that make a real difference: stop eating canned foods (a single can of soup can contain over 1,000 mg of sodium), choose frozen foods without preservatives, and check salt substitutes with your care team since many contain potassium, which interacts with common heart failure medications.
Exercise recommendations vary by type. For dilated cardiomyopathy, moderate aerobic activity like walking or stationary cycling is generally encouraged and improves quality of life. For hypertrophic cardiomyopathy, guidelines have historically been more restrictive. The 2015 AHA/ACC statement limited people with HCM to low-intensity sports (below 50% of peak oxygen capacity). High-intensity activities like basketball, soccer, cycling, swimming, rowing, and long-distance running (above 75% of peak capacity) were specifically discouraged. More recent expert opinion has softened slightly for well-evaluated patients with low-risk features, but competitive high-intensity sports remain off-limits for most people with HCM.
Advanced Options for End-Stage Disease
When cardiomyopathy progresses to the point where medications and devices no longer control symptoms, two options remain: a mechanical heart pump (left ventricular assist device, or LVAD) and heart transplantation.
Heart transplantation remains the gold standard, with a one-year survival rate of approximately 90% and a median survival of 12.5 years. The limiting factor is donor organ availability, which means many patients wait months to years on the transplant list.
LVADs have improved dramatically. The current generation of pumps (using magnetic levitation technology) achieves a one-year survival of 86% and a five-year survival of about 63 to 64%, according to the INTERMACS and ELEVATE registries. That’s a remarkable leap from earlier devices, which had a one-year survival of only 52% in the original REMATCH trial. LVADs can serve as a bridge to transplant (keeping you alive and functional while you wait for a donor heart) or as permanent therapy if transplant isn’t an option.
Living with an LVAD means carrying a small external controller and battery pack, charging batteries daily, and keeping the drive-line exit site (where a cable exits your skin) clean to prevent infection. Most patients return to daily activities, and many go back to work. The trade-off is ongoing maintenance and the need for blood-thinning medication to prevent clots inside the pump.
Gene Therapy on the Horizon
For hypertrophic cardiomyopathy caused by mutations in the MYBPC3 gene (the most common genetic cause of HCM), a first-in-human gene therapy trial is underway. The MyPeak-1 trial, led by Cleveland Clinic and sponsored by Tenaya Therapeutics, is testing a one-time intravenous infusion that delivers a functional copy of the gene using a viral vector. Initial results from six patients (presented at the American Heart Association’s 2025 Scientific Sessions) are being evaluated for safety and early signs of efficacy. This approach is still in early-phase testing, but it represents the first attempt to address the root genetic cause of HCM rather than managing its downstream effects.